Patent US5124339A successfully refreshed from Google Patents.
US5124339A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
Assignee: SmithKline Beecham Corp
•
Filing: 1990-06-18
•
Granted: 1992-06-23
•
Expires: 2010-06-18
Abstract
Abstract Potentiating agents which enhance the efficacy of antineoplastic agents are disclosed. The potentiating agents disclosed are 2-(aminoethylamino) pyridines such as (E)-3-(6-(N-(2-Dimethylaminoethyl)-4-methoxybenzylamino)-2-pyridyl)acrylic acid.
Inventors
- 👤 Ann C. King
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 07:19
CPC Classifications
C; C07; C07D; C07D295/00; C07D295/04; C07D295/06; C07D295/073; A; A61; A61K; A61K31/00; A61K31/33; A61K31/335; A61K31/395; A61K31/40; A61K31/435; A61K31/44; A61K31/495; A61K31/55; C07D213/00; C07D213/02; C07D213/04; C07D213/24; C07D213/54; C07D213/55; C07D213/56; C07D295/08; C07D295/096; C07D295/14; C07D295/155; C07D313/00; C07D313/02; C07D313/06; C07D313/10; C07D313/12
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
130 words
A method of combating multiple drug resistance of susceptible tumor cells in a subject in need of such treatment, comprising administering to the subject a compound, in an amount effective to combat multiple drug resistance of tumor cells sensitive to said compound, wherein said compound is selected from the group consisting of ##STR3## wherein: R 1 is selected from the class consisting of halogen, --COOH, --CH═CH--COOH, --CH 2 COOH, and --(CH 2 ) 2 COOH; R 2 is selected from the class consisting of hydrogen, halogen, C 1-4 alkoxy and C 1-4 alkyl; and R 3 and R 4 are the same or different and are selected from the class consisting of hydrogen and C 1-4 alkyl, or NR 3 R 4 is pyrrolidino; and the pharmaceutically acceptable salts thereof.
Claim 2
Independent Claim
130 words
A method of combating multiple drug resistance of susceptible tumor cells in a subject in need of such treatment, comprising administering to the subject a compound, in an amount effective to combat multiple drug resistance of tumor cells sensitive to said compound, wherein said compound is selected from the group consisting of ##STR3## wherein: R 1 is selected from the class consisting of halogen, --COOH, --CH═CH--COOH, --CH 2 COOH, and --(CH 2 ) 2 COOH; R 2 is selected from the class consisting of hydrogen, halogen, C 1-4 alkoxy and C 1-4 alkyl; and R 3 and R 4 are the same or different and are selected from the class consisting of hydrogen and C 1-4 alkyl, or NR 3 R 4 is pyrrolidino; and the pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim
24 words
A method according to claim 1, wherein R 1 is bromo, R 2 is methoxy, R 3 is methyl, and R 4 is methyl.
Claim 4
Dependent Claim
12 words
A method according to claim 1, wherein said compound is (E)-3-(6-(N-(2-Dimethylaminoethyl)-4-methoxy-benzylamino)-2-pyridyl)acrylic acid.
Claim 5
Dependent Claim
12 words
A method according to claim 1, wherein said compound is N-(5-Bromo-2-pyridyl)-N-(4-methoxybenzyl)-N',N'-dimethyl-1,2-ethanediamine hydrobromide.
Claim 6
Dependent Claim
13 words
A method according to claim 1, wherein said tumor cells are adenocarcinoma cells.
References Cited (Backward Citations)
US3996222A
Cited
GB2120941A
Cited
US4628047A
Cited
US4590199A
Cited
JPS6185320A
Cited
EP0187700A1
Cited
EP0270926A2
Cited
EP0353692A2
Cited
EP0361485A2
Cited
US4990538A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-06-23 | 1995-12-23 | 1996-06-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-06-23 | 1999-12-23 | 2000-06-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-06-23 | 2003-12-23 | 2004-06-23 | $7700.00 | Window Closed / Lapsed |